UCLB CEO highlights university spinout success in Financial Times Feature

UCLB’s CEO Dr. Anne Lane shared her insights on the vast opportunities that universities can gain from commercialisation in a Financial Times feature on university technology spinouts.

The article explores the financial pressures faced by UK universities and underscores the potential of technology and life sciences spinouts as revenue sources.

Dr. Lane highlighted UCL’s impressive track record in generating revenue from its research, stressing the importance of not dominating equity and intellectual property to attract investors. Last year alone, UCLB contributed £6 million in gift aid to UCL and generated an additional £18 million in revenues from groundbreaking inventions such as Roctavian, a gene therapy treatment for haemophilia A. Currently, UCLB has 95 active spinout companies and 24 advanced therapeutics in clinical trials.

“Academics want to get involved because it gives their work real-world impact. If anyone hoped to [fully] finance research with spinouts, it would be a long wait,” Lane says.

 

Read the full article here (£): Universities should not be greedy with technology spin-offs